Navigation Links
Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
Date:9/1/2010

SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • Robert W. Baird 2010 Health Care Conference on Tuesday, September 14, 2010 at 8:30 a.m. Eastern Time at The St. Regis Hotel in New York City.
  • UBS Global Life Sciences Conference 2010 on Tuesday, September 21, 2010 at 10:00 a.m. Eastern Time at the Grand Hyatt New York in New York City.
  • 5th Annual JMP Securities Healthcare Conference on Monday, September 27, 2010 at 9:00 a.m. Eastern Time at The New York Palace in New York City.

  • (Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

    (Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

    Live audio webcasts of these presentations will be accessible on the Company's website at www.optimerpharma.com, under the investors section.  Replays of these presentations will be available at the same location for 30 days after the presentations.

    About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  In two Phase 3 trials completed by Optimer to study the safety and efficacy of fidaxomicin for the treatment of CDI, fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurre
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
    2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
    3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
    5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
    7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
    8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/5/2015)... Bio-Techne Corporation (NASDAQ: TECH ) announced ... a dividend of $0.32 per share for the quarter ... payable May 29, 2015 to all common shareholders of ... be considered by the Board of Directors on a ... ) is a global life sciences company providing innovative ...
    (Date:5/5/2015)... 5, 2015  InMed Pharmaceuticals Inc. ("InMed") (CSE: ... that specializes in developing safer, more effective cannabis-based ... investor, and Non-Executive Director, Peter Mountford , ... with primary responsibility for the European markets. ... leverage his previous success in the emerging field ...
    (Date:5/4/2015)... May 4, 2015  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, ... financial results for the first quarter ended March 31, ... "Following our equity offering in February, ... we are in a strong financial position to ...
    Breaking Medicine Technology:InMed Engages Peter Mountford as Strategic Advisor 2InMed Engages Peter Mountford as Strategic Advisor 3InMed Engages Peter Mountford as Strategic Advisor 4Xencor Reports First Quarter 2015 Financial and Operating Results 2Xencor Reports First Quarter 2015 Financial and Operating Results 3Xencor Reports First Quarter 2015 Financial and Operating Results 4Xencor Reports First Quarter 2015 Financial and Operating Results 5Xencor Reports First Quarter 2015 Financial and Operating Results 6Xencor Reports First Quarter 2015 Financial and Operating Results 7Xencor Reports First Quarter 2015 Financial and Operating Results 8
    ... the journal Blood found 92 percent reduction in ... ... Patients with a rare,blood disorder called PNH experienced a 92 ... treatment,with Soliris(TM) (eculizumab), according to an analysis of clinical studies,recently ...
    ... Groundbreaking 2002 ... ... study reveals that,coiling, a minimally invasive procedure to treat aneurysms in ... treatment in those aneurysms considered "untouchable" by the,traditional surgical option. One ...
    Cached Medicine Technology:PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 2New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 3
    (Date:5/5/2015)... RF Technologies®, a leading provider of personal safety ... Solution with Voice Alarms. The ST750 will play a ... wait for assistance when it detects them starting to ... different melodies or tones or silent alerting, by integrating ... Alert®. , For 28 years, Sensatec Fall Management ...
    (Date:5/5/2015)... Rafael, CA (PRWEB) May 05, 2015 ... in 2012, with the belief that ultimate Frisbee™ is ... be the next sport that engages the world. Nike ... youth level, by creating opportunities for young athletes to ... this collaboration with MLU the perfect fit. , The ...
    (Date:5/5/2015)... 05, 2015 NovaSom, Inc., announced today ... of Innovations with Ed Begley Jr., airing via Discovery ... , This segment will focus on NovaSom, a leader ... learn about their AccuSom® home sleep test, which is ... continuous patient support and next-day test results and interpretation. ...
    (Date:5/5/2015)... 2015 Every year, news articles appear warning ... the worst dry eye season is spring, also known as ... of the United States. The only season offering a respite ... Kleyne, host of the Sharon Kleyne Hour™ Power of Water® ... show of May 11, 2015. Kleyne is the inventor of ...
    (Date:5/5/2015)... 05, 2015 McMunn Associates , ... automation solutions, announced today that it has officially launched ... identity. According to president and founder, Larry McMunn, the ... the company’s strategy for growth and expansion for the ... the past 30 years by building close, personal relationships ...
    Breaking Medicine News(10 mins):Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3Health News:McMunn Associates Launches New Corporate Branding with New Website 2
    ... treatments, better patient outcomes , , WEDNESDAY, March 12 (HealthDay ... patients at risk of developing acute kidney injury (AKI) ... problem would otherwise be detected, a pilot study shows. ... better patient outcomes, the researchers say. , The test ...
    ... sights on renewed growth, IRWINDALE, Calif., March 12 ... including diet bars and,powdered mixes, today announced the appointment ... and consumer products sectors: Allan,Lutz, Scott Meader and Hugh ... of the company., Mr. Lutz has more than ...
    ... first "test-tube" baby was born in July 1978 - the ... couples in developed countries. There, we have seen more than ... in some countries, as many as 4 per cent of ... The plight of couples in developing countries, especially women, has ...
    ... market, WASHINGTON, March 12 Groundbreaking research,on ... impact on Medicare costs. The new study by,America,s ... in the,journal Health Affairs. AHIP also released a ... Medigap enrollment has remained constant in recent,years, showing ...
    ... ISTA,Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced ... Health Care Conference at 3:55 p.m. Eastern,Daylight Time on ... Hotel,in Boston, MA., ISTA,s President and Chief Executive ... the Company,s commercial and clinical,progress. To access the live ...
    ... announces Progress in Osteoporosis now available FREE online , ... mouse click away , The International Osteoporosis Foundation has ... is now available free online to help readers keep ... developments. , Progress in Osteporosis provides a timely update ...
    Cached Medicine News:Health News:New Test Predicts Risk of Post-Surgery Kidney Injury 2Health News:Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer 2Health News:Fertility in developing countries: words into action 2Health News:New AHIP Study in Health Affairs Challenges Previous Assumptions About Medigap's Impact on Medicare Costs 2Health News:New AHIP Study in Health Affairs Challenges Previous Assumptions About Medigap's Impact on Medicare Costs 3
    ... RiOs systems produce Type III, laboratory-grade ... Systems are fed directly with potable tap ... a compact system design that is easy ... over the water produced at a low ...
    ... ArcticTemp Ultra Low Freezers -85C offer efficiency ... Features: Compressor life is extended by an ... a constant flow of refigerant. Heat is ... condenser with three fans. Monitoring light to ...
    ... U570 is an upright freezer, built ... models. Comparable in size to Innova ... cascade refrigeration and urethane insulation, for ... 400 2" boxes. Includes five compartments ...
    ... freezer, with over 23 cu. ft. storage ... Built to the same standards as Innova ... cost-saving alternative. Rust-resistant, powder coated exterior; top-quality ... adjustable shelves. Keyed lock and 4-digit password ...
    Medicine Products: